Nintedanib is a tyrosine kinase inhibitor that interacts with key receptors involved in the regulation of crucial pathogenetic processes in pulmonary fibrosis. Therefore, it is approved for the treatment of adult Idiopathic Pulmonary Fibrosis. In pediatric patients, this therapeutic option has not yet been approved but could improve the landscape for children with interstitial lung disease.